Kaplan-Meier estimates of survival among the study patients randomized to maintenance therapy.

Progression-free survival (A) and overall survival (B). Survival was measured from the time of randomization to maintenance therapy. Median progression-free survival is 14 months on the high-dose arm and 5 months on the low-dose arm; P = .003. Median survival is 37 months on the high-dose arm and 26 months on the low-dose arm;P =  .05.